Pay in 4 interest-free payments of $6.56 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
The upcoming SURMOUNT-MAINTAIN trial, expected to report results around mid-2026, will specifically compare the 5 mg maintenance dose against higher doses for weight maintenance after initial loss
Concomitantly, mean systolic blood pressure declines by 35 mmHg, with modest LDL improvements, providing biologically plausible support for downstream cardiovascular risk reduction
Engages the GIP receptor Targets glucose-dependent insulinotropic polypeptide a metabolic pathway most weight-management medications leave untouched
The theoretical advantage is dual-pathway GH stimulation and potentially greater elevation
US$ 22.63
US$ 25.58
US$ 24.24
US$ 26.93
US$ 27.36
US$ 26.03
